60 Degrees Pharmaceuticals (SXTP) Research & Development (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Research & Development of $281464.0 for Q1 2026, down 24.1% year-over-year from $370813.0 in Q1 2025, and down 55.94% quarter-over-quarter from $638873.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Research & Development (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Research & Development for 5 consecutive years, with $281464.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 24.1% year-over-year to $281464.0; the TTM figure through Mar 2026 stood at $2.0 million (down 60.56% YoY), while the FY2025 annual figure was $2.1 million, down 57.76% from the prior year.
- Research & Development slipped to $281464.0 in Q1 2026 per SXTP's latest filing, from $638873.0 in the prior quarter.
- Across five years, Research & Development topped out at $3.1 million in Q2 2024 and bottomed at $27655.0 in Q3 2022.
- Historically, Research & Development has averaged $530725.8 across 5 years, with a median of $272583.5 in 2023.
- Annual changes were most pronounced in 2024 — Research & Development soared 1418.27% — and 2025, when it tumbled 91.93%.
- 60 Degrees Pharmaceuticals' Research & Development stood at $203457.0 in 2022, then slumped by 50.75% to $100201.0 in 2023, then soared by 512.72% to $613955.0 in 2024, then gained by 4.06% to $638873.0 in 2025, then sank by 55.94% to $281464.0 in 2026.
- Business Quant data shows SXTP's Research & Development at $281464.0 in Q1 2026, $638873.0 in Q4 2025, and $809777.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | 60 Degrees Pharmaceuticals | 2.97 Mn | 1.95 Mn | 56,798.00 | 598,653.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 281,464.00 |
| Dec 31, 2025 | 638,873.00 |
| Sep 30, 2025 | 809,777.00 |
| Jun 30, 2025 | 249,884.00 |
| Mar 31, 2025 | 370,813.00 |
| Dec 31, 2024 | 613,955.00 |
| Sep 30, 2024 | 940,063.00 |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 337,182.00 |
| Dec 31, 2023 | 100,201.00 |
| Sep 30, 2023 | 263,703.00 |
| Jun 30, 2023 | 203,872.00 |
| Mar 31, 2023 | 123,994.00 |
| Dec 31, 2022 | 203,457.00 |
| Sep 30, 2022 | 27,655.00 |
| Jun 30, 2022 | 231,394.00 |